| 12.83 -0.05 (-0.39%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.35 | 1-year : | 19.09 |
| Resists | First : | 14 | Second : | 16.35 |
| Pivot price | 13.02  |
|||
| Supports | First : | 12.2 |
Second : | 11.1 |
| MAs | MA(5) : | 12.82  |
MA(20) : | 12.69 |
| MA(100) : | 10.41 |
MA(250) : | 9.05 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 47.1 |
D(3) : | 48.8 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 14 | Low : | 6.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DXR ] has closed above bottom band by 43.1%. Bollinger Bands are 74.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.94 - 13.01 | 13.01 - 13.07 |
| Low: | 12.48 - 12.58 | 12.58 - 12.66 |
| Close: | 12.68 - 12.83 | 12.83 - 12.96 |
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Mon, 06 Oct 2025
Daxor Corporation (NASDAQ:DXR) Short Interest Down 34.7% in September - MarketBeat
Tue, 30 Sep 2025
Daxor (NASDAQ:DXR) Trading 7.6% Higher - What's Next? - MarketBeat
Tue, 23 Sep 2025
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting - GlobeNewswire
Tue, 23 Sep 2025
3X Faster Blood Testing: Daxor's Revolutionary FDA-Cleared Heart Failure Analyzer Changes Patient Care - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.98e+006 (%) |
| Held by Institutions | 2.15e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 66310 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 2 % |
| Operating Margin | 710.8 % |
| Return on Assets (ttm) | -1 % |
| Return on Equity (ttm) | 509.4 % |
| Qtrly Rev. Growth | 5.2 % |
| Gross Profit (p.s.) | 0.31 |
| Sales Per Share | -0.01 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 80.18 |
| Price to Sales | -1.06193e+006 |
| Price to Cash Flow | 0 |
| Dividend | 18640 |
| Forward Dividend | 38250 |
| Dividend Yield | 145284% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|